TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
14 hedge funds and large institutions have $4.11M invested in TFF Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
7% less funds holding
Funds holding: 15 → 14 (-1)
19% less capital invested
Capital invested by funds: $5.08M → $4.11M (-$977K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$376K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$258K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55K |
| 4 |
BlackRock
New York
|
+$46K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$85K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$73K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$43.8K |
| 4 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$32.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$18.9K |
TFFP Hedge Fund Activity: Q1 2020 in Review
14 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q1 2020, worth a combined $4.11M — down 19% from $5.08M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TFFP and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Sigma Planning Corp, adding an estimated $376K. The largest seller was Goldman Sachs, exiting entirely with an estimated $85K sold.
- 14 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q1 2020, down from 15 in Q4 2019.
- Funds reported $4.11M of TFF Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 19% quarter-over-quarter.
- 2 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 3 closed out, a net change of -1 holder.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Sigma Planning Corp, an estimated $376K added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Goldman Sachs, an estimated $85K sold.
Based on aggregated 13F filings for Q1 2020.